Navigation Links
Ferring Pharmaceuticals To Develop Major Corporate Center in Parsippany, New Jersey
Date:11/21/2011

PARSIPPANY, N.J., Nov. 21, 2011 /PRNewswire/ -- Switzerland-based Ferring Pharmaceuticals today announced the purchase of a 25-acre site at 100 Interpace Parkway in Parsippany, N.J.  The new facility will house a state-of-the art, expanded U.S. Operations Center. The expansion is expected to generate jobs in the New Jersey area, countering recent trends in the pharmaceutical industry.

The U.S. Operations Center will be a fully integrated pharmaceutical facility that will house management, administration and support, commercial operations, manufacturing and product development.  It will include a state-of-the-art manufacturing suite, next-generation product development laboratories, a fully equipped education and training conference center, and administrative offices.

"As a private company, Ferring has a long term orientation, as well as a commitment to follow the science to benefit patients. This new facility underscores our long-term commitment to the U.S. market, as well as the State of New Jersey," said Aaron Graff, President and Chief Operating Officer of Ferring Pharmaceuticals, Inc. 

"Together with our Global Research Center in San Diego, this symbolizes our focus on accelerating Ferring growth in the United States.  The local community has continuously expressed support for our endeavors, and we are so pleased to expand our operations in an area with such a large base of talented, highly trained pharmaceutical professionals." 

The Switzerland-based company has experienced consistent double-digit growth in the U.S. and has approximately 600 U.S. employees. Globally Ferring has nearly 5,000 employees with operations in more than 45 countries.

About Ferring Pharmaceuticals Inc.

Ferring Pharmaceuticals Inc. is a subsidiary of Ferring Pharmaceuticals, a privately owned, global pharmaceutical company. Ferring Pharmaceuticals offers a line of products in the U.S. market. They include: BRAVELLE® (urofollitropin for injection, purified), MENOPUR® (menotropins for injection, USP) and REPRONEX® (menotropins for injection, USP), NOVAREL® (chorionic gonadotropin for injection, USP), ENDOMETRIN® (progesterone) Vaginal Insert, LYSTEDA® (tranexamic acid tablets), FIRMAGON® (degarelix for injection), and EUFLEXXA® (1% sodium hyaluronate).

Ferring Pharmaceuticals specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, gastroenterology, infertility, obstetrics/gynecology, orthopaedics and urology. For more information, call 1-888-FERRING (1-888-337-7464) or visit www.FerringUSA.com.

All registered trademarks above are owned by Ferring B.V.

 


'/>"/>
SOURCE Ferring Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Ferring Pharmaceuticals Inc. Congratulates All 2011 Summer National Senior Games Athletes
2. Ferring Pharmaceuticals to Support Great Prostate Cancer Challenge® Events Across the Country in National Effort to End Prostate Cancer
3. Ferring Celebrates Winners of 2010 My Little Miracle Essay Contest During National Infertility Awareness Week
4. Ferring Pharmaceuticals, Inc. Congratulates R&B and Pop Icon Gloria Gaynor, Named Woman of the Year by Arthritis Foundation
5. Ferring Pharmaceuticals FIRMAGON® Joins Race to End Prostate Cancer as Official Sponsor of the Great Prostate Cancer Challenge / Dash for Dad
6. Ferring Pharmaceuticals FIRMAGON® Named Official Sponsor of Ed Randalls Bat for the Cure
7. Ferring Pharmaceuticals Announces Disco Icon Gloria Gaynor as National Spokesperson for EUFLEXXA(R)
8. Ferring Acquires LYSTEDA(TM) From Xanodyne Pharmaceuticals, Inc.
9. Ferring Pharmaceuticals and Gene Security Network Partner to Test Advanced Preimplantation Genetic Diagnosis (PGD) Technology
10. Dr. Harry Kovelman Joins Ferring Pharmaceuticals as Associate Medical Director for Orthopaedics
11. Timm Medical Technologies and Ferring Pharmaceuticals Enter Exclusive Co-Promotion Agreement for Prosed(R) DS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 VolitionRx ... of Dr. Edward Futcher to the ... effective June 23, 2016.Dr. Futcher was also appointed ... Governance Committees.  As a non-executive member of the ... and strategic counsel to VolitionRx in connection with ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
(Date:6/23/2016)... 2016  In a startling report released today, National Safety ... lacking a comprehensive, proven plan to eliminate prescription opioid overdoses. ... how states are tackling the worst drug crisis in recorded U.S. ... Kentucky , New Mexico , ... Of the 28 failing states, three – Michigan ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... "With 30 hand-drawn ... specific project," said Christina Austin - CEO of Pixel Film Studios. , ProHand ... all within Final Cut Pro X . Simply select a ProHand generator and ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
(Date:6/24/2016)... ... 24, 2016 , ... The Pulmonary Hypertension Association (PHA) learned ... receive two significant new grants to support its work to advance research and ... by recognizing patients, medical professionals and scientists for their work in fighting pulmonary ...
(Date:6/24/2016)... ... 2016 , ... People across the U.S. are sharpening their pencils and honing ... contest in which patients and their families pay tribute to a genetic counselor by ... Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. , In ...
(Date:6/24/2016)... ... ... National recruitment firm Slone Partners is pleased to announce the ... as Vice President of North American Capital Sales at HTG Molecular . ... team in the commercialization of the HTG EdgeSeq system and associated reagents in North ...
Breaking Medicine News(10 mins):